Orthocell receives new US patent for CelGro®

~ New US divisional patent granted for CelGro®

~ Patent covers the method of manufacture of collagen medical devices and as an aid in the surgical repair of soft tissue injuries

~ CelGro® patents have been previously granted in the US, Canada, Europe, China, Japan, Singapore, Australia and New Zealand

~ CelGro® dental (recently renamed Striate+) approved for use in US, Europe and Australia

~ Global addressable market for CelGro® is in excess of >US$10bn1 and growing.

DISC: I Hold

CelGro® receives Australian market approval

? Orthocell receives Australian market approval to supply CelGro® in dental bone and tissue regeneration procedures

? Validates the CelGro® platform technology and positions Orthocell to achieve further approvals in nerve and tendon repair

? Potential for Australian reimbursement by Q2 CY2021 which will assist with further technical and market validation for CelGro®

? Positions Orthocell well for US FDA approval targeted for CY2021

It already has EU approval.

DISC: I have small holding